Galena Biopharma Inc (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of …
Analysts are weighing in today on Galena Biopharma Inc (NASDAQ:GALE) with mixed ratings, as the company released its second-quarter earnings results after the …
Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of …
In a research report published yesterday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Galena Biopharma Inc (NASDAQ:GALE) with an $8.00 price target, after …
Galena Biopharma Inc. (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of …
Roth Capital analyst Joseph Pantginis offered commentary on Galena Biopharma Inc (NASDAQ:GALE) following the presentation of the Phase 2 clinical trial of GALE-401 at the …
Maxim’s healthcare analyst Jason Kolbert weighed in today with a favorable report on Galena Biopharma Inc (NASDAQ:GALE), after the company reported the presentation of two abstracts at …
